Narcolepsy Drugs Market Size & Share, by Disease Type (Extreme Sleepiness, Cataplexia); Therapeutics Type (Central Nervous System Stimulants, Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitor, Sodium Oxybate); End-user (Retail Pharmacies, Drug Stores, E-Commerce) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2035

  • Report ID: 2767
  • Published Date: Apr 26, 2023
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2023-2035

Narcolepsy Drugs Market anticipated to reach USD 11.6 Billion by the end of 2035, growing at a CAGR of 10% during the forecast period i.e., 2023-2035. In the year 2022, the industry size of narcolepsy drugs was over USD 3.3 Billion. The rising prevalence of narcolepsy globally owing to the stressful lifestyle along with the surge in consumption of alcohol and tobacco is one of the major factors estimated to drive the growth of the narcolepsy drugs. As per the report, approximately 20% of American adults smoke, while 64% use alcoholic beverages regularly.

The market growth is also attributed to the increasing demand for the latest therapies to cure the disorder and rising healthcare expenditure in various emerging economies. Further, there is a significant rise in the activities of research & development for the development of highly effective drugs on the back of unhealthy lifestyles of people. Between 2000 and 2018, global health expenditure increased steadily, reaching US$ 8.3 trillion, or 10% of the global GDP.

The creation of drugs for narcolepsy treatment has accelerated dramatically in recent years. Furthermore, administrations in nations including India and South Africa are encouraging the manufacturing of narcolepsy drugs due to the health benefits, which are projected to enhance the narcolepsy drugs industry growth throughout the forecast period.

Narcolepsy Drugs Market
Get more information on this report: Request Free Sample PDF

Narcolepsy Drugs Sector: Growth Drivers and Challenges

  • Rising Understanding Regarding Narcolepsy Disorders- The active involvement of various organizations globally to spread awareness related to the disorder and its symptoms is propelling the growth of the market. In addition, the rising knowledge regarding the treatment of narcolepsy and sleep disorders is leading to the rise in narcolepsy awareness programs. Further, increased concerns regarding the advantages of early diagnosis of narcolepsy drugs along with the promotions by governments to educate people & trained professionals regarding the disorder are accelerating the growth of the market. Therefore, these factors are estimated to drive the demand for the narcolepsy drugs market during the forecast period. Based on the study "Narcolepsy Presentation in Diverse Populations: an Update" released in November 2020, narcolepsy influences 0.87-1.21% of the worldwide population.
  • Market participants' approval and introduction of new pharmaceuticals- Approval and launch of novel medications by market players are expected to play an important role in propelling market expansion in the next years. For instance, the FDA approved Avadel's New Drug Application (NDA) for FT218, an experimental, once-nightly composition of sodium oxybate employed for the treatment of high levels of drowsiness and cataplexy in people with narcolepsy, in March 2021.
  • The growing incidence of narcolepsy around the world is projected to drive the industry- A report released in January 2022 titled "Prevalence, incidence, and health care utilization of patients with narcolepsy: a population-representative study" revealed that the early prevalence of narcolepsy in Europe is 0.64-1.37 per 100,000. 
  • Geriatric population growth worldwide- By 2030, one in every six persons on the globe is estimated to be 60 or older. The global population of individuals aged 60 and up will double (2.1 billion) by 2050.
  • Extreme Psychological Stress- As of 2022, 19.86% of adults are suffering from a mental illness. The equivalent of roughly 50 million Americans. 4.91% have a severe mental disorder in America.


  • Stringent Government Regulations- Stringent government regulations regarding the agreement for narcolepsy drugs are identified as one of the factors expected to hamper the growth of the market over the forecast period.
  • Risks Related to Narcolepsy Drugs- The ill effects of narcolepsy drugs along with the possibility of delay in diagnosis & treatment are anticipated to hinder the growth of the market. Further, a lack of acknowledgment among patients and medical care providers in developed & developing nations is restraining the market growth of narcolepsy drugs.
  • Misdiagnosis or Postponed diagnosis 

Narcolepsy Drugs Market: Key Insights

Base Year


Forecast Year




Base Year Market Size (2022)

~ USD 3.3 Billion

Forecast Year Market Size (2035)

~ USD 11.6 Billion

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Get more information on this report: Request Free Sample PDF

Narcolepsy Drugs Segmentation

Disease Type (Extreme Sleepiness, Cataplexia)

Based on disease type, the market for narcolepsy drugs is segmented into extreme sleepiness, cataplexia, and others, out of which, extreme sleepiness is estimated to witness the highest market share owing to rising cases of narcolepsy worldwide along with the other disorders. During the projection period, the daytime extreme sleepiness segment is expected to hold the highest share of the market in the entire narcolepsy drugs market. The growth in narcolepsy prevalence increases the incidence of indications and other sleep disorders. Many patients with narcolepsy and other sleep disorders are more likely to experience this symptom, boosting the need for narcolepsy medicines. As additional firms enter the narcolepsy medicines industry, growth will be accelerated.

Therapeutics Type (Central Nervous System Stimulants, Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitor, Sodium Oxybate)

The global market of narcolepsy drugs is also segmented and analyzed for demand and supply by application into Central Nervous System Stimulants, tricyclic antidepressants, selective serotonin reuptake inhibitors, sodium oxybate, and others. Amongst these three segments, the central nervous system stimulants segment is expected to garner a significant share of around ~35% in the year 2035. During the projected period, the Central Nervous System Stimulants segment is anticipated to take over the market. Therapeutics including modafinil, armodafinil, and additional central nerve stimulants for narcolepsy are focused on enhancing wakefulness in individuals with narcolepsy, based to an article published in CNS Drugs named "Recently Approved and Upcoming Treatments for Narcolepsy" in January 2021.

End-user (Retail Pharmacies, Drug Stores, E-Commerce)

Increasing studies about central nervous system stimulants is likely to fuel segment growth. Harmony Biosciences Holdings, Inc., a drug manufacturer devoted to creating and advertising cutting-edge treatments for individuals with rare neurological conditions, released an assessment of data of CNS drugs in December 2021 that assessed the period before the onset of response to pitolisant for EDS and cataplexy in grown-up patients with narcolepsy. Such research is projected to lead to the creation of innovative central nervous system stimulants, propelling the expansion of this segment. 

Our in-depth analysis of the global market includes the following segments:

       By Disease Type

  • Extreme Sleepiness
  • Cataplexia
  • Others

        By Therapeutics Type

  • Central Nervous System Stimulants
  • Tricyclic Antidepressants
  • Selective Serotonin Reuptake Inhibitor
  • Sodium Oxybate
  • Others

        By End Users

  • Retail Pharmacies
  • Drug Stores
  • E-Commerce
  • Others

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Narcolepsy Drugs Regional Synopsis

North American Market Forecast

The market in North America is anticipated to dominate the market owing to the rising prevalence of unhealthy lifestyles along with the technological advancements for the diagnosis of disease. Further, an increase in the number of narcolepsy cases leading to the rising awareness for the treatment along with rising healthcare expenditure is driving the growth of the market. Narcolepsy impacts between 135,000 and 200,000 individuals across the United States, in accordance to a data sheet published in November 2021 by the National Institute of Neurological Disorders and Stroke. However, owing to this condition is often incorrectly diagnosed, the number could be substantially higher. As a result of the elevated incidence of narcolepsy in advanced nations such as the United States, the growing use of narcolepsy treatment is expected to drive market expansion in this area.

APAC Market Statistics

The Asia Pacific region is estimated to witness the fastest growth rate on the back of economic development in major nations and rising investments in biotechnology sectors. In addition, the adoption of better standards of life and rising cases of sleep disorders is fostering the growth of the market. Japan has been identified as exhibiting a high frequency of narcolepsy among Asia Pacific countries. Governments in nations such as India are raising knowledge about the relevance of narcolepsy, which is projected to drive development in the narcolepsy drugs market over the forecast time frame. Moreover, the presence of established economic economies such as China and India is assisting in the development of healthcare facilities throughout the Asia-Pacific area. Furthermore, favorable government strategies in the Asia-Pacific region are encouraging the development of the narcolepsy drugs market. Other notable factors for expansion in this region's narcolepsy drugs market include multiple agreements between business entities and academic institutions in the region, along with an increase in the number of new products introduced, acquisitions, and product authorizations.

Europe Market Forecast

The Europe region is estimated to foresee lucrative growth on the account of rising research & development initiatives for the progress in narcolepsy novel drugs. In 2022, Europe held the second-largest market share. The key reasons for this are improved medical services and the region's growing population. This sector is also being boosted by government activities about depressive illness and its consequences. Other positive contributing elements include having finances accessible for research and operations, the expansion of the large patient population, and the increase in the number of obese people. Furthermore, the presence of established economic nations in European regions including Italy, Germany, and France. According to Eurostat, more than half of people in Europe are obese.

Research Nester
Narcolepsy Drugs Market Size
Get more information on this report: Request Free Sample PDF

Companies Dominating the Narcolepsy Drugs Landscape

    • Ligand Pharmaceuticals Incorporated 
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Jazz Pharmaceuticals Inc.
    • Graymark Healthcare Inc.
    • Novartis AG
    • Teva Pharmaceuticals Industries Ltd.
    • Arena Pharmaceuticals Inc.

In the News

  • Ligand Pharmaceuticals Incorporated and GSK declared the Licence Agreement and the global growth of their relationship. The development is expected to be fueled by Icagen's particle discovery method and expertise in small-molecule therapeutics addressing membrane proteins.
  • Teva Pharmaceutical Industries Ltd. stated that they would spend USD 69 million to settle a Narcolepsy drug lawsuit in California. The reimbursement is expected to help the corporation in maintaining its monopoly in an industry where the rival corporation's Narcolepsy drugs will postpone their release by nearly six months.

Author Credits:  Radhika Pawar

  • Report ID: 2767
  • Published Date: Apr 26, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

The rising prevalence of narcolepsy globally owing to the stressful lifestyle along with the surge in consumption of alcohol and tobacco is one of the major factors estimated to drive the growth of narcolepsy drugs market.

The market is anticipated to attain a moderate CAGR of 10% over the forecast period, i.e., 2023-2035.

Stringent government regulations regarding the agreement for narcolepsy drugs is identified as one of the factors expected to hamper the growth of the market over the forecast period.

The market in North America is estimated to garner the largest market share owing to the growing construction industry in the region, which creates further growth opportunities.

The major players in the market are Jazz Pharmaceuticals Inc., Graymark Healthcare Inc., BIOPROJET, Novartis AG, Teva Pharmaceuticals Industries Ltd., Arena Pharmaceuticals Inc., and others.

The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.

The market is segmented by disease type, therapeutics type, end users, and by region.

the extreme sleepiness segment is anticipated to hold largest market over the forecast period.
Narcolepsy Drugs Market Report Scope

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying